Find clinical trials for Lymphoma in San Francisco, CA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lymphoma trials near San Francisco, CA, USA:
in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas...
Phase 3
Burlingame, California, United States
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherap...
Phase 2
Palo Alto, California, United States and 7 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
San Francisco, California, United States and 66 other locations
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...
Phase 2
San Francisco, California, United States and 59 other locations
and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...
Phase 1, Phase 2
Palo Alto, California, United States and 73 other locations
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas....
Phase 1
San Francisco, California, United States and 7 other locations
in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in...
Phase 1, Phase 2
San Francisco, California, United States
is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma...
Phase 1
San Francisco, California, United States and 3 other locations
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...
Phase 2
San Francisco, California, United States and 94 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma...
Phase 1, Phase 2
Stanford, California, United States and 3 other locations
Clinical trials
Research sites
Resources
Legal